Rockwell Medical Receives FDA Approval For Calcitriol
WIXOM, Mich., June 23, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced that the FDA has approved the Company's Supplemental Abbreviated New Drug Application (sANDA) to manufacture Calcitriol. Calcitriol is Rockwell's low-cost generic active vitamin D drug.
Help employers find you! Check out all the jobs and post your resume.